Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin

Vaccine

Volumn 30, Issue 46, 2012, Pages 6527-6533

  Liu, Xiaoyu ^a   Guo, Jianqiang ^a   Han, Su ^b   Yao, Lihong ^a   Chen, Aijun ^a   Yang, Qi ^a   Bo, Hong ^a   Xu, Pengwei ^a   Yin, Jiyong ^a   Zhang, Zhiqing ^a  

^a Institute for Viral Disease Control and Prevention   (China)

^b NANKAI UNIVERSITY   (China)

Author keywords

Branched peptide; Influenza vaccine; M2e antigen; Tuftsin

Indexed keywords

ANTIVIRUS AGENT; GLYCINE; INFLUENZA VACCINE; MATRIX PROTEIN 2; TUFTSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DESIGN; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROVOCATION TEST; SOLID; SURVIVAL RATE; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; DISEASE MODELS, ANIMAL; FEMALE; INFLUENZA VACCINES; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; TUFTSIN; VIRAL MATRIX PROTEINS;

EID: 84867002553     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.08.054     Document Type: Article

References (33)

1. Tosh P.K., Tosh R.M., Poland G.A. Influenza vaccines: from surveillance through production to protection. Mayo Clin Proc 2010, 85:257-273.
2. Stanekova Z., Vareckova E. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J 2010, 7:351-363.
3. Fiers W., Filette M.D., Bakkouri K.E., Schepens B., Roose K., Schotsaert M., et al. M2e-based universal influenza A vaccine. Vaccine 2009, 27:6280-6283.
4. Ebrahimi S.M., Tebianian M. Influenza A viruses: why focusing on M2e-based universal vaccines. Virus Genes 2011, 42:1-8.
5. Zebedee S.L., Lamb R.A. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 1988, 62:2762-2772.
6. Ernst W.A., Kim H.J., Tumpey T.M., Jansen A.D.A., Tai W., Cramer D.V., et al. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 2006, 24:5158-5168.
7. Zou P., Liu W.L., Chen Y.H. The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection. Int Immunopharmacol 2005, 5:631-635.
8. Jegerlehner A., Schmitz N., Storni T., Bachmann M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004, 172:5598-5605.
9. Subbarao K., Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 2007, 7:267-278.
10. Wu F., Huang J.H., Yuan X.Y., Huang W.S., Chen Y.H. Characterization of immunity induced by M2e of influenza virus. Vaccine 2007, 25:8868-8873.
11. Filette M.D., Martens W., Roose K., Deroo T., Vervalle F., Bentahir M., et al. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem 2008, 283:11382-11387.
12. Schotsaert M., Filette M.D., Fiers W., Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009, 8(4):499-508.
13. De Filette M., Martens W., Smet A., Schotsaert M., Birkett A., Londoño-Arcila P., et al. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine 2008, 26(51):6503-6507.
14. Tompkins S.M., Zhao Z.S., Lo C.Y., Misplon J.A., Liu T., Ye Z.P., et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007, 13(3):426-435.
15. Fan J., Liang X.P., Horton M.S., Perry H.C., Citron M.P., Heidecker G.J., et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22:2993-3003.
16. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26(2):201-214.
17. Liu W., Peng Z., Liu Z., Lu Y., Ding J., Chen Y.H. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine 2004, 23(3):366-371.
18. Tam J.P. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci USA 1988, 85:5409-5413.
19. Ota S., Ono T., Morita A., Uenaka A., Harada M., Nakayama E. Cellular processing of a multibranched lysine core with tumor antigen peptides and presentation of peptide epitopes recognized by cytotoxic T lymphocytes on antigen-presenting cells. Cancer Res 2002, 62:1471-1476.
20. Ciesielski M.J., Kazim A.L., Barth R.F., Fenstermaker R.A. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model. Cancer Immunol Immunother 2005, 54:107-119.
21. Knittelfelder R., Riemer A.B., Jarolim E.J. Mimotope vaccination - from allergy to cancer. Expert Opin Biol Ther 2009, 9:493-506.
22. Kelker H.C., Itri V.R., Valentine F.T. A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein. PLoS ONE 2010, 5:e8555.
23. Zhao G.Y., Lin Y.P., Du L.Y., Guan J., Sun S.H., Sui H.Y., et al. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J 2010, 7:9-17.
24. Taborda C.P., Nakaie C.R., Cilli E.M., Rodrigues E.G., Silva L.S., Franco M.F., et al. Synthesis and immunological activity of a branched peptide carrying the T-cell epitope of gp43, the major exocellular antigen of Paracoccidioides brasiliensis. Scand J Immunol 2004, 59:58-65.
25. Ridi R.E., Tallima H. Schistosoma mansoni ex vivo lung-stage larvae excretory-secretory antigens as vaccine candidates against schistosomiasis. Vaccine 2009, 27:666-673.
26. Mozdzanowska K., Feng J.Q., Eid M., Kragol G., Cudic M., Otvos L., et al. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003, 21:2616-2626.
27. Gokulan K., Khare S., Rao D.N. Increase in the immunogenicity of HIV peptide antigens by chemical linkage to polytuftsin (TKPR40). DNA Cell Biol 1999, 18:623-630.
28. Mezö G., Kalászi A., Reményi J., Majer Z., Hilbert á., Láng O., et al. Synthesis, conformation, and immunoreactivity of new carrier molecules based on repeated tuftsin-like sequence. Biopolymers 2004, 73:645-656.
29. Feng J.Q., Zhang M.X., Mozdzanowska K., Zharikova D., Hoff H., Wunner W., et al. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 2006, 3:102-114.
30. Wang R.F., Song A.H., Levin J., Dennis D., Zhang N.J., Yoshida H., et al. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antivir Res 2008, 80:168-177.
31. Bakkouri K.E., Descamps F., Filette M.D., Smet A., Festjens E., Birkett A., et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 2011, 186:1022-1031.
32. Brown D.M., Roman E., Swain S.L. CD4 T cell responses to influenza infection. Semin Immunol 2004, 16:171-177.
33. Guo Y.J., Cheng X.W. Influenza virus and correlation technique 1997, China Sanxia Publishing House, Beijing.